Alcobra Ltd. (ADHD) Upgraded by WBB Securities to “Buy”

WBB Securities upgraded shares of Alcobra Ltd. (NASDAQ:ADHD) from a hold rating to a buy rating in a report published on Monday morning. The brokerage currently has $2.00 price target on the biotechnology company’s stock.

ADHD has been the topic of several other research reports. Zacks Investment Research upgraded shares of Alcobra from a hold rating to a buy rating and set a $1.25 price target on the stock in a research report on Tuesday, July 18th. Jefferies Group LLC reaffirmed a hold rating and issued a $1.25 price objective on shares of Alcobra in a research note on Monday, June 12th. Finally, Roth Capital lowered shares of Alcobra from a buy rating to a neutral rating and decreased their price objective for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $1.56.

Alcobra (NASDAQ:ADHD) opened at 1.09 on Monday. Alcobra has a 52 week low of $0.83 and a 52 week high of $2.70. The firm’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.11. The stock’s market cap is $30.04 million.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Analysts expect that Alcobra will post ($0.50) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Alcobra Ltd. (ADHD) Upgraded by WBB Securities to “Buy”” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/alcobra-ltd-adhd-upgraded-by-wbb-securities-to-buy.html.

Institutional investors have recently bought and sold shares of the stock. Royce & Associates LP boosted its stake in Alcobra by 15.5% in the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after purchasing an additional 100,000 shares during the period. Citadel Advisors LLC boosted its stake in Alcobra by 7,251.0% in the 1st quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 101,514 shares during the period. Finally, Worth Venture Partners LLC boosted its stake in Alcobra by 35.6% in the 2nd quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 71,465 shares during the period. 29.68% of the stock is owned by hedge funds and other institutional inv

ADHD has been the topic of several other research reports. Zacks Investment Research upgraded shares of Alcobra from a hold rating to a buy rating and set a $1.25 price target on the stock in a research report on Tuesday, July 18th. Jefferies Group LLC reaffirmed a hold rating and issued a $1.25 price objective on shares of Alcobra in a research note on Monday, June 12th. Finally, Roth Capital lowered shares of Alcobra from a buy rating to a neutral rating and decreased their price objective for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $1.56.

Alcobra (NASDAQ:ADHD) opened at 1.09 on Monday. Alcobra has a 52 week low of $0.83 and a 52 week high of $2.70. The firm’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.11. The stock’s market cap is $30.04 million.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Analysts expect that Alcobra will post ($0.50) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Alcobra Ltd. (ADHD) Upgraded by WBB Securities to “Buy”” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/alcobra-ltd-adhd-upgraded-by-wbb-securities-to-buy.html.

Institutional investors have recently bought and sold shares of the stock. Royce & Associates LP boosted its stake in Alcobra by 15.5% in the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after purchasing an additional 100,000 shares during the period. Citadel Advisors LLC boosted its stake in Alcobra by 7,251.0% in the 1st quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 101,514 shares during the period. Finally, Worth Venture Partners LLC boosted its stake in Alcobra by 35.6% in the 2nd quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 71,465 shares during the period. 29.68% of the stock is owned by hedge funds and other institutional investors.

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply